PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance. Tumour cells frequently overexpress the ligand for PD-1, programmed cell death ligand 1 (PD-L1), facilitating their escape from the immune system. Monoclonal antibodies that block the interaction between PD-1 and PD-L1, by binding to either the ligand or receptor, have shown notable clinical efficacy in patients with a variety of cancers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma. Although it is well established that PD-1-PD-L1 blockade activates T cells, little is known about the role that this pathway may have in tumour-associated macrophages (TAMs). Here we show that both mouse and human TAMs express PD-1. TAM PD-1 expression increases over time in mouse models of cancer and with increasing disease stage in primary human cancers. TAM PD-1 expression correlates negatively with phagocytic potency against tumour cells, and blockade of PD-1-PD-L1 in vivo increases macrophage phagocytosis, reduces tumour growth and lengthens the survival of mice in mouse models of cancer in a macrophage-dependent fashion. This suggests that PD-1-PD-L1 therapies may also function through a direct effect on macrophages, with substantial implications for the treatment of cancer with these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and treatment with checkpoint inhibitors targeting PD-1 or PD-L1 increases phagocytosis and reduces tumor growth [329].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“In human and mouse CRC tumor models, high levels of PD-1 expression on TAM have low tumor phagocytosis”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“Tumor-associated macrophages were also recently shown to express PD-1 in both mice and humans with colorectal cancer and to impair macrophage phagocytosis (59).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Cited by
Items 901–1,000 of 1,001
Koga, N., Hu, Q., Sakai, A., Takada, K., Nakanishi, R., Hisamatsu, Y., Ando, K., Kimura, Y., Oki, E., Oda, Y., et al. (2021) · Cancer Science · doi:10.1111/cas.14971 · Cited by 30
Patil, R., Sun, T., Rashid, M. H., Israel, L. L., Ramesh, A., Davani, S., Black, K. L., Ljubimov, A. V., Holler, E., & Ljubimova, J. Y. (2021) · Nanomaterials · doi:10.3390/nano11112892 · Cited by 28
Inhibition of myeloid PD-L1 suppresses osteoclastogenesis and cancer bone metastasis
Zuo, H., & Wan, Y. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00446-5 · Cited by 27
Liu, Z., Tao, R. X., Lin, Z., Xie, S., Zhou, B., Fu, M., Mai, L., Zhu, C., Wu, G., & Wang, Y. (2022) · Cancers · doi:10.3390/cancers14205081 · Cited by 28
Zhao, M., He, Y., Zhu, N., Song, Y., Hu, Q., Wang, Z., Ni, Y., & Ding, L. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02090-0 · Cited by 30
Smith, B. C., Tinkey, R. A., Brock, O. D., Mariam, A., Habean, M. L., Dutta, R., & Williams, J. L. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02917-4 · Cited by 28
Wang, B., Mao, Z., Ye, J., Jiao, X., Zhang, T., Wang, Q., Han, S., Zhang, Y., Wang, C., Dong, T., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300339 · Cited by 30
Bandini, S., Ulivi, P., & Rossi, T. (2024) · Cells · doi:10.3390/cells13040337 · Cited by 29
Unravelling immune microenvironment features underlying tumor progression in the single-cell era
Du, Q., An, Q., Zhang, J., Liu, C., & Hu, Q. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03335-z · Cited by 30
Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors
Askoxylakis, V., Arvanitis, C., Wong, C. S. F., Ferraro, G. B., & Jain, R. K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.011 · Cited by 28
Activation of phagocytosis by immune checkpoint blockade
Li, C., Lai, Y., Hsu, J. L., & Hung, M. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0657-5 · Cited by 29
Understanding the complexity of tumor-associated macrophages: Druggable and therapeutic insights
Li, A.-Q., Huang, F., Talaiti, S., Yang, X. Y., Bi, H., & Fang, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.021 · Cited by 31
Targeting phagocytosis checkpoints for cancer immunotherapy
Veillette, A., Li, J., Galindo, C. C., Davidson, D., & Tang, Z.-H. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00893-w · Cited by 32
ERMAP is a B7 family-related molecule that negatively regulates T cell and macrophage responses
Su, M., Lin, Y., Cui, C., Tian, X., & Lai, L. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0494-8 · Cited by 28
A vasculature-centric approach to developing novel treatment options for glioblastoma
Wirsching, H., Roth, P., & Weller, M. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1881062 · Cited by 28
The Prognostic Value of PERK in Cancer and Its Relationship With Immune Cell Infiltration
Wang, P., Han, L., Yu, M., Cao, Z., Li, X., Shao, Y., & Zhu, G. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.648752 · Cited by 31
Huo, J., Wu, L., & Zang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635324 · Cited by 28
Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner
Etxebeste-Mitxeltorena, M., del Rincón-Loza, I., & Martín-Antonio, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717850 · Cited by 28
Jiang, L., Fei, H., Yang, A., Zhu, J., Sun, J., Liu, X., Xu, W., Yang, J., & Zhang, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.011 · Cited by 26
The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy?
Mojsilović, S. S., Mojsilović, S. B., Villar, V. H., & Santibanez, J. F. (2021) · Analytical Cellular Pathology · doi:10.1155/2021/5523055 · Cited by 27
Liao, G., Zhao, Z., Qian, Y., Ling, X., Chen, S., Li, X., & Kong, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.774131 · Cited by 26
Moradinasab, S., Pourbagheri‐Sigaroodi, A., Ghaffari, S. H., & Bashash, D. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108499 · Cited by 26
Millian, D. E., Saldarriaga, Ó. A., Wanninger, T. G., Burks, J. K., Rafati, Y., Gosnell, J., & Stevenson, H. L. (2022) · Cancers · doi:10.3390/cancers14081861 · Cited by 28
Poh, A. R., Love, C. G., Chisanga, D., Steer, J. H., Baloyan, D., Chopin, M., Nutt, S. L., Rautela, J., Huntington, N. D., Etemadi, N., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl7882 · Cited by 28
Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma
Zhu, Y., & Qin, L. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.08.003 · Cited by 29
The role of tumor-associated macrophages and soluble mediators in pulmonary metastatic melanoma
Xiong, K., Qi, M., Stoeger, T., Zhang, J., & Chen, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1000927 · Cited by 28
Wang, Z., Zhong, H., Liang, X., & Ni, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1024921 · Cited by 34
Wang, S., Vong, L. B., Heger, Z., Zhou, Y., Liang, X., Adam, V., & Li, N. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101769 · Cited by 26
A key driver to promote HCC: Cellular crosstalk in tumor microenvironment
Liu, P., Lingyu, K., Liu, Y., Li, G., Xie, J., & Lu, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135122 · Cited by 30
Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?
Pellerino, A., Bruno, F., Soffietti, R., & Rudà, R. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01417-1 · Cited by 28
Han, Z., Wu, X., Qin, H., Yuan, Y., Schmolze, D. B., Su, C., Zain, J. M., Moyal, L., Hodak, E., Sanchez, J. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.163518 · Cited by 32
Li, Z., Guo, M., Lin, W., & Huang, P. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102897 · Cited by 27
Bewersdorf, J. P., Shallis, R. M., Sharon, E., Park, S., Ramaswamy, R., Roe, C. E., Irish, J. M., Caldwell, A. B., Wei, W., Yacoub, A., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05552-4 · Cited by 28
HMMR triggers immune evasion of hepatocellular carcinoma by inactivation of phagocyte killing
Wu, H., Liu, Y., Liu, Q., Li, Z., Wan, Y., Cao, C., Wu, B., Liu, M., Liang, R., Hu, L., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl6083 · Cited by 29
Tanio, A., Saito, H., Uejima, C., Takaya, S., Yamamoto, M., Tokuyasu, N., Sakamoto, T., Honjo, S., Ashida, K., & Fujiwara, Y. (2018) · Surgery Today · doi:10.1007/s00595-018-1728-6 · Cited by 29
Dost, F. S., Kırmızı, B. A., Ensarı, A., İçlı, F., & Akbulut, H. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.12.004 · Cited by 26
Arthur, P., Patel, N., Surapaneni, S. K., Mondal, A., Gebeyehu, A., Bagde, A., Kutlehria, S., Nottingham, E., & Singh, M. S. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115112 · Cited by 27
Polesso, F., Munks, M. W., Rott, K. H., Smart, S. M., Hill, A. B., & Moran, A. E. (2021) · European Journal of Immunology · doi:10.1002/eji.202048960 · Cited by 27
Gusak, A., Fedorova, L. V., Lepik, K. V., Volkov, N. P., Popova, M. O., Moiseev, I., Mikhailova, N. B., Baykov, V., & Kulagin, A. (2021) · Cancers · doi:10.3390/cancers13225676 · Cited by 25
Artificial Nanovesicles Derived from Cells: A Promising Alternative to Extracellular Vesicles
Lou, S., Hu, W. H., Wei, P., He, D., Fu, P., Ding, K., Chen, Z., Dong, Z., Zheng, J., & Wang, K. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c12567 · Cited by 28
Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity
Moreno‐Sanchez, P. M., Rezaeipour, M., Inderberg, E. M., Platten, M., & Golebiewska, A. (2026) · Nature Cancer · doi:10.1038/s43018-025-01097-9 · Cited by 39
Horio, D., Minami, T., Kitai, H., Ishigaki, H., Higashiguchi, Y., Kondo, N., Hirota, S., Kitajima, K., Nakajima, Y., Koda, Y., et al. (2020) · Cancer Science · doi:10.1111/cas.14523 · Cited by 26
Redirecting macrophage function to sustain their “defender” antitumor activity
Tzetzo, S. L., & Abrams, S. I. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.002 · Cited by 27
Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer
Feng, Z., Yin, Y., Liu, B., Zheng, Y., Shi, D., Zhang, H., & Qin, J. (2022) · Cancer Control · doi:10.1177/10732748221076682 · Cited by 25
Wu, D., Liu, X., Mu, J., Yang, J., Wu, F., & Zhou, H. (2022) · Biomolecules · doi:10.3390/biom12030392 · Cited by 29
Pham, T. D., Spaulding, C., Shields, M. A., Metropulos, A. E., Shah, D. N., Khalafalla, M. G., Principe, D. R., Bentrem, D. J., & Munshi, H. G. (2022) · JCI Insight · doi:10.1172/jci.insight.152731 · Cited by 25
CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia
Allouch, A., Voisin, L., Zhang, Y., Raza, S. Q., Lécluse, Y., Calvo, J., Selimoglu‐Buet, D., de Botton, S., Louache, F., Pflumio, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34548-3 · Cited by 29
Recent advances and emerging therapies in anaplastic thyroid carcinoma
Cabanillas, M. E., Zafereo, M., Williams, M. D., Ferrarotto, R., Dadu, R., Gross, N. D., Gunn, G. B., Skinner, H. D., Cote, G. J., Grosu, H. B., et al. (2018) · F1000Research · doi:10.12688/f1000research.13124.1 · Cited by 25
Scherwitzl, I., Hurtado, A. M., Pierce, C. M., Vogt, S., Pampeno, C., & Meruelo, D. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.04.004 · Cited by 26
Zhu, Q., Wu, X., Tang, M., & Wu, L. (2020) · Medicine · doi:10.1097/md.0000000000019839 · Cited by 26
Papalampros, A., Vailas, M. G., Ntostoglou, K., Chiloeches, M. L., Sakellariou, S., Chouliari, N. V., Samaras, M. G., Veltsista, P. D., Theodorou, S. D. P., Margetis, A., et al. (2020) · Cancers · doi:10.3390/cancers12071825 · Cited by 29
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle
Marchetti, A., Lorito, A. D., & Buttitta, F. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.11.105 · Cited by 25
van Duijn, A., Willemsen, K. J., van Uden, N. O. P., Hoyng, L., Erades, S., Koster, J., Luiten, R. M., & Bakker, W. J. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-03007-1 · Cited by 24
Understanding and overcoming resistance to immunotherapy in genitourinary cancers
Evans, S. T., Jani, Y. C., Jansen, C. S., Yıldırım, A., Kalemoglu, E., & Bilen, M. A. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2342599 · Cited by 26
Osteomyelitis is associated with increased anti-inflammatory response and immune exhaustion
Surendar, J., Hackenberg, R. K., Schmitt-Sánchez, F., Ossendorff, R., Welle, K., Stoffel‐Wagner, B., Sage, P. T., Burger, C., Wirtz, D. C., Strauss, A. C., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1396592 · Cited by 27
Lorestani, P., Dashti, M., Nejati, N., Habibi, M. A., Askari, M., Robat-Jazi, B., Ahmadpour, S., & Tavakolpour, S. (2024) · Discover Oncology · doi:10.1007/s12672-024-01256-x · Cited by 27
Xiao, S., Xu, R. Y., Yang, Y., Zhao, R., Xie, Y., Lei, X.-D., & Wu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1431535 · Cited by 26
Non-canonical PD-1 signaling in cancer and its potential implications in clinic
Zha, H., Jiang, Y., Wang, X., Shang, J., Wang, N., Yu, L., Zhao, W., Li, Z., Zhang, X., Zhang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001230 · Cited by 25
PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours
Turchini, J., Sioson, L., Clarkson, A., Sheen, A., & Gill, A. J. (2021) · Endocrine Pathology · doi:10.1007/s12022-021-09673-2 · Cited by 24
Checkpoints and immunity in cancers: Role of GNG12
Alausa, A. O., Victor, U. C., Fadahunsi, O. S., Owolabi, N., Adeniji, A., Olatinwo, M., Ogunlana, A. T., Olaleke, B., Balogun, T. A., Ogundepo, S., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106242 · Cited by 25
Lepland, A., Malfanti, A., Haljasorg, U., Asciutto, E. K., Pickholz, M., Bringas, M., Đorđević, S., Salumäe, L., Peterson, P., Teesalu, T., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0043 · Cited by 26
Myeloid checkpoints for cancer immunotherapy
Qian, Y., Yang, T., Liang, H., & Deng, M. (2022) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2022.05.07 · Cited by 25
Chen, Q., Chen, B., Wang, C., Hu, L., Wu, Q., Zhu, Y., & Zhang, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1159085 · Cited by 27
Guo, X., Song, J., Liu, M., Ou, X., & Guo, Y. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2356831 · Cited by 26
Mehrabi, M., Amini, F., & Mehrabi, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00235 · Cited by 25
Emerging biomarkers in ovarian granulosa cell tumors
Mills, A. M., Chinn, Z., Rauh, L. A., Dusenbery, A. C., Whitehair, R. M., Saks, E. J., & Duska, L. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2018-000065 · Cited by 24
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
Fujimura, T., Sato, Y., Tanita, K., Lyu, C., Kambayashi, Y., Amagai, R., Otsuka, A., Fujisawa, Y., Yoshino, K., Matsushita, S., et al. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00086 · Cited by 27
PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma
Jiang, F., Yu, W., Zeng, F., Cheng, G., Xu, J., Yang, S., Shui, Y., Wu, D., Xiao-fang, Y., & Wei, Q. (2019) · BMC Cancer · doi:10.1186/s12885-019-5689-y · Cited by 25
Tamura, R., Morimoto, Y., Sato, M., Kuranari, Y., Oishi, Y., Kosugi, K., Yoshida, K., & Toda, M. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03388-5 · Cited by 25
The Adaptive and Innate Immune Cell Landscape of Uterine Leiomyosarcomas
Manzoni, M., Bolognesi, M. M., Antoranz, A., Mancari, R., Carinelli, S. G., Faretta, M., Bosisio, F. M., & Cattoretti, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-57627-1 · Cited by 27
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
Bocanegra, A., Blanco, E., Fernández-Hinojal, G., Arasanz, H., Chocarro, L., Zuazo, M., Morente, P., Vera, R., Escors, D., & Kochan, G. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165918 · Cited by 25
Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy
Dougan, M. L. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0372 · Cited by 26
Menter, T., Tzankov, A., & Dirnhofer, S. (2020) · Hematological Oncology · doi:10.1002/hon.2821 · Cited by 24
The effect of PD-1 expression on tumor-associated macrophage in T cell lymphoma
Ruan, J., Ouyang, M., Zhang, W., Luo, Y., & Zhou, D. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02499-0 · Cited by 26
What is the burden of proof for tumor mutational burden in gliomas?
Khasraw, M., Walsh, K. M., Heimberger, A. B., & Ashley, D. M. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa256 · Cited by 28
Dahl, O., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1555375 · Cited by 24
Lin, Y., Ding, J. L., Shen, H.-T., Lin, Y.-M., Adhidjaja, E. C., & Chang, S. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09105-7 · Cited by 25
Lu, Y., Guo, L., & Ding, G. (2019) · Future Oncology · doi:10.2217/fon-2019-0519 · Cited by 25
Jin, Y., Yu, G., Hu, P., Yang, C., Li, X., Chen, X., Wei, Q., & Wang, J. (2020) · Immunologic Research · doi:10.1007/s12026-020-09155-3 · Cited by 23
Kubon, J., Sikic, D., Eckstein, M., Weyerer, V., Stöhr, R., Neumann, A., Keck, B., Wullich, B., Hartmann, A., Wirtz, R. M., et al. (2020) · Cancers · doi:10.3390/cancers12102794 · Cited by 23
Ma, T., Jin, J., Huo, R., Li, X., Fang, G., Zhao, Q., Liu, W., Han, X., Xi, C., Wang, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.922899 · Cited by 29
Knowledge landscape of tumor-associated macrophage research: A bibliometric and visual analysis
Zhou, F., Liu, Y., Liu, C., Wang, F., Peng, J., Xie, Y., & Zhou, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1078705 · Cited by 24
Emerging Progress of RNA-Based Antitumor Therapeutics
Fu, J., Dong, H., Wu, J., & Jin, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83732 · Cited by 24
Zhang, Y., Zhang, Y., Li, Y., Fu, Y., Zhao, Y., Zhao, W. H., Li, R., Xian, Y., Tu, K., Wu, F., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.145685 · Cited by 24
Li, S., Chen, D., Guo, H., Yang, Y., Liu, D., Yang, C., Bai, X., Zhang, W., Zhang, L., Zhao, G., et al. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad020 · Cited by 23
Brauneck, F., Oliveira‐Ferrer, L., Muschhammer, J., Sturmheit, T., Ackermann, C., Haag, F., Wiesch, J. S. Z., Ding, Y., Qi, M., Hell, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1250258 · Cited by 25
Chou, C., Hung, C., Chiu, C. H.-L., Tan, X., Chen, M., Chen, C., Saeed, M., Hsu, C., Liss, M. A., Wang, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42303-5 · Cited by 28
PD-1H/VISTA mediates immune evasion in acute myeloid leukemia
Kim, T. K., Han, X. N., Hu, Q., Vandsemb, E. N., Fielder, C. M., Hong, J., Kim, K. W., Mason, E. F., Plowman, R. S., Wang, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci164325 · Cited by 28
Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy
Lecoultre, M., Walker, P. R., & Helali, A. E. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01443-8 · Cited by 27
Li, Z., Li, M., Liu, Y., Chen, J., Ye, Q., Qian, W., & Wang, S. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009473 · Cited by 25
Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy
Park, S., & Kim, I. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.018 · Cited by 24
Aldawsari, H. M., Gorain, B., Alhakamy, N. A., & Md, S. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1648478 · Cited by 23
Sun, P., Zhang, L., Gu, Y., Wei, S., Wang, Z., Li, M., Wang, W., Wang, Z., & Bai, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111955 · Cited by 28
Hei, Y., Yang, C., Li, Q., Mei, Z., Pan, J., Zhang, S., Xiong, C., Su, X., & Wei, S. (2021) · Small · doi:10.1002/smll.202105118 · Cited by 27
Immune-Related Adverse Events: Pneumonitis
Jain, A., Shannon, V. R., & Sheshadri, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_6 · Cited by 25
Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
Liu, W. R., & Shipp, M. A. (2017) · Hematology · doi:10.1182/asheducation-2017.1.310 · Cited by 28
Matusiak, M., Hickey, J. W., Luca, B. A., Lu, G., Kidziński, Ł., Zhu, S., Colburg, D. R. C., Phillips, D. J., Brubaker, S. W., Charville, G. W., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2393443/v1 · Cited by 24
Miao, X., Wu, X., You, W., He, K., Chen, C., Pathak, J. L., & Zhang, Q. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05451-w · Cited by 26
Cheng, Y., Han, X., Lai, X., & Wei, X. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156093 · Cited by 25
Tian, S., Xu, M., Geng, X., Fang, J., Xu, H., Xue, X., Hu, H., Zhang, Q., Yu, D., Guo, M., et al. (2024) · Advanced Science · doi:10.1002/advs.202410285 · Cited by 34
Metadata
- Authors
- Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., Ring, A. M., Connolly, A. J., & Weissman, I. L.
- Affiliations
- Stanford Medicine (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Yale University (US)
- Corresponding author
- Weissman, Irving L.
- ORCID
- Venue
- Nature
- Published
- 2017-05
- Volume
- 545
- Issue
- 7655
- Pages
- 495-499
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5931375
- OpenAlex
- W2615301036
- Cited by
- 2,247
- References
- 34
- Citations by year
- 2026: 167 · 2025: 261 · 2024: 303 · 2023: 298 · 2022: 309 · 2021: 299 · 2020: 264 · 2019: 158 · 2018: 135 · 2017: 51
- FWCI
- 75.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Science Foundation
- Cancer Research Institute
- A.P. Giannini Foundation
- Giannini Foundation of Agricultural Economics
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (155336)
- National Institutes of Health (1s10rr026780-01)
- National Cancer Institute (R01CA086017, P30CA124435)
- National Institute of General Medical Sciences (T32GM007365)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR050942)
- National Center for Research Resources (1S10RR02678001, 1S10RR026780, S10 RR026780)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- PD-1, tumour-associated macrophages, PD-L1, phagocytosis, immune checkpoint blockade, tumour immunity, cancer immunotherapy, tumour-infiltrating macrophages
- MeSH terms
- Animals, Colonic Neoplasms, Disease Models, Animal, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Neoplasm Staging, Phagocytosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.